Strata Skin Sciences Inc Stock Price, News & Analysis

STRATA Skin Sciences (NASDAQ: SSKN) is actively working with CMS to accelerate access to expanded reimbursement for its XTRAC® excimer laser treatment ahead of the planned January 1, 2027 implementation. The American Medical Association's CPT Editorial Panel has approved updates to expand reimbursement eligibility to include all inflammatory and autoimmune skin conditions, potentially making treatments accessible by 2026.

This expansion could triple the addressable market to over 30 million patients. Two recent peer-reviewed studies validate the efficacy of combining 308-nm excimer-laser therapy with JAK inhibitors for vitiligo treatment, showing a 100% overall response rate and 96% pigment stability. Additionally, the company provided updates on its ongoing litigation against LaserOptek regarding false advertising claims.

STRATA Skin Sciences (NASDAQ: SSKN), a medical technology company focused on dermatologic treatments, has scheduled its Q2 2025 earnings release for August 13, 2025 after market close.

The company will host a conference call at 4:30 p.m. ET the same day, featuring management remarks and a Q&A session. Investors can access the call via phone (U.S.: 1-866-524-3160, International: 1-412-317-6760) or through a live webcast. A replay will be available until August 20, 2025, using code 4200962.

STRATA Skin Sciences (NASDAQ: SSKN) announces a significant expansion of CPT codes for its XTRAC® Excimer Laser treatments. The American Medical Association has revised CPT codes 96920-96922 to include multiple inflammatory and auto-immune skin conditions beyond psoriasis. This expansion increases the addressable market from 10 million to over 30 million potential patients, including those with vitiligo (3M), atopic dermatitis (16.5M), and alopecia areata (4.6M). The change eliminates the need for prior authorizations and is expected to reduce systemic denials. Currently, non-psoriasis conditions represent 30% of excimer laser procedures. STRATA's XTRAC platform is present in 1,400 clinics with 4,000 medical providers domestically, with approximately 850 recurring revenue devices in the United States.

STRATA Skin Sciences (NASDAQ: SSKN) reported Q1 2025 financial results with revenue of $6.8 million, up 1% year-over-year. The company's gross margin improved significantly to 53.5%, up 790 basis points from 45.6% in Q1 2024. Global recurring XTRAC® revenue was $4.5 million, with international growth of 27% offsetting a 4% domestic decline. Operating expenses decreased by 5% to $5.7 million, and Adjusted EBITDA improved by $732,000 to negative $547,000. The company's direct-to-consumer strategy showed strong results, with Psoriasis and Acne patient growth of 32% and 128% respectively. International revenue grew 8% in Q1, now representing 36% of total revenue. The company reported a net loss of $2.4 million, or negative $0.58 per share, compared to a loss of $3.4 million in Q1 2024.

STRATA Skin Sciences (NASDAQ: SSKN), a medical technology company focused on dermatologic treatments, announces its participation in the D. Boral Capital Inaugural Global Conference on May 14, 2025. The event will take place at The Plaza Hotel in New York City, where CEO Dr. Dolev Rafaeli will conduct one-on-one meetings from 9:00 AM to 3:00 PM ET. Interested parties can register for meetings through John Perez at D. Boral Capital.

STRATA Skin Sciences (NASDAQ: SSKN), a medical technology company focused on dermatologic treatments, has scheduled its first quarter 2025 financial results announcement for May 14, 2025 after market close. The company will host a conference call at 5:00 p.m. ET the same day, featuring management remarks and a Q&A session.

Interested U.S. participants can join via phone at 1-866-524-3160 (domestic) or 1-412-317-6760 (international). A live webcast will also be available. The call replay will be accessible until May 21, 2025, through multiple channels including phone (1-877-344-7529 or 1-412-317-0088) with access code 6753445, and webcast replay available until September 21, 2025.

STRATA Skin Sciences (NASDAQ: SSKN) reported Q4 2024 financial results with revenue of $9.6 million, up 10% year-over-year. The company's global XTRAC® recurring revenue reached $5.5 million, while equipment revenue increased 23% to $3.8 million.

Full-year 2024 revenue was $33.6 million, slightly up from $33.4 million in 2023. Q4 gross margin improved to 60.1%, up 480 basis points from the previous year. The company reduced its domestic XTRAC® installed base to 864 devices while increasing average revenue per device to $5,906 (+6% YOY).

Notable developments include renewed 3-year agreements with distributors in China and Japan, XTRAC Momentum™ 1.0 device approval in Japan, and a $2.1 million registered direct offering. The company reported a net loss of $4.5 million for Q4 2024 and ended the year with $8.6 million in cash and equivalents.

STRATA Skin Sciences (NASDAQ: SSKN), a medical technology company focused on dermatologic treatments, has scheduled its Fourth Quarter and Year End 2024 financial results announcement for March 27, 2025 after market close.

The company will host a conference call at 4:30 p.m. ET on the same day, featuring management's remarks and a Q&A session. Investors can access the call through domestic (1-844-481-2523) or international (1-412-317-0552) dial-in numbers.

A webcast replay will be available until September 21, 2025, while telephonic replay access will be available until April 3, 2025 using the code 8210574.

STRATA Skin Sciences (NASDAQ: SSKN) announces results from a new Japanese study validating the superiority of narrow band Excimer Laser over Excimer Light for treating skin conditions. The study, published in the Journal of Nippon Medical School, demonstrates that despite both devices using 308-nm wavelength, the Excimer Laser's unique properties lead to better clinical outcomes.

Key findings show that XTRAC® Excimer Laser achieves:

• Deeper penetration into hair follicles
• Greater activation of melanocyte lineage cells
• Fewer epidermal side effects
• Faster treatment delivery (1 second vs 20 seconds for 1,000 mJ/cm²)

STRATA has expanded its presence in Japan with over 100 devices placed, including 24 in 2024. The company's global footprint includes over 1,800 devices in the United States and 1,000 internationally.